Drug Profile
V 3526
Alternative Names: V3526; VEE 3526; VEE IA/B V3526; VEE Vaccine; Venezuelan equine encephalitis virus vaccine - DynPortLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator United States Army Medical Research Institute of Infectious Diseases; University of North Carolina at Chapel Hill
- Developer Charles River Laboratories; DynPort Vaccine Company
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Venezuelan equine encephalomyelitis
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Venezuelan-equine-encephalomyelitis in USA (SC, Injection)
- 31 Oct 2006 Northwest Kinetics has been acquired by Charles River Laboratories
- 27 Mar 2006 Dynport and Northwest Kinetics have initiated a phase I trial for Encephalitis virus infections in USA